Sofinnova Management X, L.L.C. 4
4 · CinCor Pharma, Inc. · Filed Jan 13, 2022
Insider Transaction Report
Form 4
Sofinnova Venture Partners X, L.P.
10% Owner
Transactions
- Purchase
Common Stock
2022-01-11$16.00/sh+325,000$5,200,000→ 5,573,949 total(indirect: By Sofinnova Venture Partners X, L.P.) - Conversion
Series A Preferred Stock
2022-01-11−13,571,428→ 0 total(indirect: By Sofinnova Venture Partners X, L.P.)→ Common Stock (3,991,596 underlying) - Conversion
Series B Preferred Stock
2022-01-11−4,275,000→ 0 total(indirect: By Sofinnova Venture Partners X, L.P.)→ Common Stock (1,257,353 underlying) - Conversion
Common Stock
2022-01-11+5,248,949→ 5,248,949 total(indirect: By Sofinnova Venture Partners X, L.P.)
Footnotes (2)
- [F1]Each share of Series A Preferred Stock and Series B Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering (the "IPO") for no additional consideration, on a 3.4:1 basis, and had no expiration date.
- [F2]The shares are directly held by Sofinnova Venture Partners X, L.P. ("SVP X"). Sofinnova Management X, L.L.C. ("SM X") is the general partner of SVP X. Dr. James I. Healy and Dr. Maha Katabi are managing members of SM X and may be deemed to share voting and investment power over the shares held by SVP X. Each of SM X and Dr. Katabi disclaims beneficial ownership of these shares except to the extent of its or her respective pecuniary interest therein. Dr. Healy is a director of the Issuer and files separate Section 16 reports.